Tsunoda T, Tanimura H, Yamaue H, Iwahashi M, Tani M, Tamai M, Arii K, Noguchi K
Department of Gastroenterological Surgery, Wakayama Medical College, Japan.
Biotherapy. 1992;4(1):9-15. doi: 10.1007/BF02171704.
In adoptive immunotherapy, the number of effector cells is one of the major factors relating to the therapeutic efficacy. We demonstrated that tumor-infiltrating lymphocytes (TILs) were stimulated to proliferate by incubation with interleukin 2 (IL-2) plus interleukin 4 (IL-4). TILs cultured with IL-2 plus IL-4 increased 3.1-fold more than TILs cultured with IL-2 alone. However, IL-4 did not alter the cytotoxic activity of TILs against autologous tumor cells and established tumor cell lines. It is suggested that IL-2 receptor is related to the mechanism of the proliferation of activated TILs cultured by combination with IL-2 and IL-4. Thus, the combination of IL-2 and IL-4 may increase the efficacy of adoptive immunotherapy using activated TILs.
在过继性免疫治疗中,效应细胞的数量是与治疗效果相关的主要因素之一。我们证明,肿瘤浸润淋巴细胞(TILs)通过与白细胞介素2(IL-2)加白细胞介素4(IL-4)孵育而被刺激增殖。用IL-2加IL-4培养的TILs比单独用IL-2培养的TILs增加了3.1倍。然而,IL-4并未改变TILs对自体肿瘤细胞和已建立的肿瘤细胞系的细胞毒性活性。提示IL-2受体与IL-2和IL-4联合培养的活化TILs增殖机制有关。因此,IL-2和IL-4的联合使用可能会提高使用活化TILs的过继性免疫治疗的疗效。